Concepedia

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Mignon L. Loh, Sarah K. Tasian, Karen R. Rabin, Patrick A. Brown, Daniel Magoon, Joel M. Reid, Xuejun Chen, Charlotte H. Ahern, Brenda J. Weigel, Susan M. Blaney

Pediatric Blood & Cancer · 2015 · 126 citations · 25 references

DOI

Abstract

Ruxolitinib was well tolerated in children with refractory cancer. The recommended phase 2 dose for continuous BID oral administration is 50 mg/m(2)/dose. Subsequent evaluation of ruxolitinib in combination with cytotoxic chemotherapy in children, adolescents, and young adults with JAK-mutant leukemias is planned.

References

25

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Kirk R. Schultz, W. Paul Bowman, Alexander Aledo et al. · Journal of Clinical Oncology · 2009 · 700 citations · Full text

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Ryan D. Morin, Jinghui Zhang et al. · Cancer Cell · 2012 · 699 citations · Full text

, , +9